A Phase 4 interventional study of Bio K+® 2 capsules orally (or via nasogastric tube) and Placebo in Clostridium Difficile Infection and Antibiotic Associated Diarrhea, sponsored by Bio-K Plus International Inc.. Terminated at 1 site in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Bio-K Plus International Inc. (part of Kerry Group plc) · Phase 4, Interventional, and Prevention
Antibiotic-associated diarrhea (AAD) and particularly Clostridium difficile-Infection (CDI) are the most common causes of healthcare associated infectious diarrhea. In light of the results obtained in a limited number of randomized clinical trials in subjects with AAD and CDI in comparison with the widespread occurrence of these diseases, it is felt that the addition of a well-controlled clinical trial in a western environment would add value to support the use of a specific probiotic to counteract these diseases.
The prevalence of Clostridium difficile infection (CDI) has been on the rise in the United States, and in fact the Centers for Disease Control and Prevention (CDC) identified CDI as one of the highest threats in its recent report on antibiotic resistance in the United States. This designation as an "urgent threat" highlights the need for immediate and aggressive action to prevent this infection.
In fact, CDI has been reported as the most commonly reported pathogen causing healthcare-associated infections (HAIs). A point prevalence survey of 183 hospitals in 10 states found that C. difficile comprised 12.1% of HAIs, surpassing Staphylococcus aureus infections.
Although most cases of CDI can be treated successfully with relatively safe and effective oral antibiotics (i.e., metronidazole or vancomycin), primary prevention of CDI is critical because up to one in five treated patients endures a relapse or reinfection, which can be difficult to treat; infected patients serve as a reservoir for ongoing transmission within facilities; implementation of contact isolation precautions for patients who have CDI can have deleterious consequences for the patient; and, CDI can result in death or severe disease including those treated by colectomy. Because CDI is spread between patients, prevention of a single case should reduce the risk of exposure for other hospital patients.
One of the main studies in this indication, being a quality improvement study conducted at Pierre Le Gardeur Hospital (PLGH) in province of Québec, Canada. Starting in 2004, 10 years of surveillance data were reported from this hospital that administers Bio-K Plus to all antibiotic users. During the 10 years of observation, 44, 835 inpatients received Bio-K+, and the CDI rate at PLGH declined from 18.0 cases per 10,000 patient-days and remained at low mean levels of 2.3 cases per 10 000 patient-days.
Additionally, 10-year data collected by the Ministry of Health in Quebec comparing the CDI rate between Quebec hospitals showed that CDI rates at PLGH were consistently and continuously lower compared with those at similar hospitals.
In conclusion, adding Bio-K Plus as a standard treatment led to a dramatic and sustained decrease in the incidence of C. difficile infections at this hospital.
313 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.
This study's enrollment of 60 is close to the median of 64 across 235 interventional studies indexed under Clostridium Infections.
Browse Clostridium Infections studies →Bio-K Plus International Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
First submitted before Bio-K Plus International Inc. became part of Kerry Group plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Only subjects who meet the following inclusion criteria will be eligible to participate in the study:
Exclusion Criteria
Subjects who meet any of the following exclusion criteria will not be eligible to participate in the study:
Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
Dietary Supplement: Placebo
Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
Dietary Supplement: Bio K+® 2 capsules orally (or via nasogastric tube)
Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
Also known as: Bio-K+®
Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
To evaluate the incidence of Clostridium Difficile infection
The primary objective of this study is evaluate the incidence risk ratio of CDI in hospitalized subjects treated with systemic antibiotics, taking oral administration of Bio-K+® in comparison with a placebo. Risk will be calculated for the period of antibiotic treatment plus 65 days.
Time frame: 2 Years
To evaluate the incidence of antibiotic associated diarrhea
* To evaluate the incidence of AAD * To evaluate the incidence of RCDI * To determine the time to occurrence of the first symptoms (first liquid stool) of AAD or CDI - * To evaluate the impact on the duration of hospitalization * To evaluate the number of emergency room visits and re-hospitalizations for AAD or CDI * To determine the mean costs for the initial hospitalization * To evaluate the safety profile of Bio-K+®
Time frame: 2 Years
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bio-K Plus International Inc. →